Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziv-aflibercept in Advanced Carcinoid Tumors
NCT01782443Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2013
- Primary completion
- Mar 2021
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aflibercept in Carcinoid Tumor (CT), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Progression Free Survival at 2 years. Started Feb 2013; status: completed.
02
Drugs
aflibercept
03
Conditions
Carcinoid Tumor (CT)
Beyond the preview
Go deeper on NCT01782443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01782443.